Hemgenix
etranacogene dezaparvovec
Table of contents
Overview
Hemgenix is a medicine used to treat adults with severe and moderately severe haemophilia B, an inherited bleeding disorder caused by the lack of factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults who have not developed inhibitors (proteins made by the body’s natural defenses) against factor IX.
Haemophilia B is rare, and Hemgenix was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 March 2018. Further information on the orphan designation can be found here: EU/3/18/1999
Hemgenix contains the active substance etranacogene dezaparvovec and is a type of advanced therapy medicine called a ‘gene therapy product’. This is a type of medicine that works by delivering genes into the body.
-
List item
Hemgenix : EPAR - Medicine overview (PDF/119.47 KB)
First published: 28/02/2023
EMA/45357/2023 -
-
List item
Hemgenix : EPAR - Risk Management Plan (PDF/2.24 MB)
First published: 28/02/2023
Authorisation details
Product details | |
---|---|
Name |
Hemgenix
|
Agency product number |
EMEA/H/C/004827
|
Active substance |
Etranacogene dezaparvovec
|
International non-proprietary name (INN) or common name |
etranacogene dezaparvovec
|
Therapeutic area (MeSH) |
Hemophilia B
|
Anatomical therapeutic chemical (ATC) code |
B06
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Conditional approval |
This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation. |
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
CSL Behring GmbH
|
Revision |
1
|
Date of issue of marketing authorisation valid throughout the European Union |
20/02/2023
|
Contact address |
Emil-von-Behring-Straße 76 |
Product information
23/03/2023 Hemgenix - EMEA/H/C/004827 - N/0002
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Other hematological agents
Therapeutic indication
Treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.